EU/3/13/1145

About

On 19 June 2013, orphan designation (EU/3/13/1145) was granted by the European Commission to Oncos Therapeutics Oy, Finland, for genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor for the treatment of soft-tissue sarcoma.

In November 2015, Oncos Therapeutics Oy changed name to Targovax Oy.

The sponsor’s address was updated in March 2021.

Key facts

Active substance
genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor
Disease / condition
Treatment of soft tissue sarcoma
Date of first decision
19/06/2013
Outcome
Positive
EU designation number
EU/3/13/1145

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Targovax Oy  
Lars Sonckin Kaari 14
Espoo
Helsinki-Uusimaa
02600
Finland
Tel. +358 10 279 4000
E-mail: contact@targovax.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating